Fig. 1.
![Fig. 1. cPLA2 activity in neutrophil lysates of patients with sepsis or with sepsis+bacteremia. / DTT-resistant cPLA2 activity is measured by [14C]AA release from PC vesicles using neutrophil lysates from patients with sepsis or sepsis+bacteremia (“During”) and after recovery (“After”).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/95/2/10.1182_blood.v95.2.660/6/bloo00211001x.jpeg?Expires=1724232390&Signature=pbxrrFQGvuMiFrM3Q6CNW-3fDh08414nVnceHLA-uainaeJ883S0N0Mi~xipjRBppMENa-8BeiMMazUTf~SP5tGzYsmcuQ0GJpXMGqN25Tz0RWK8DqxR2fQLuU5DMUi4LODNOtdonZZXoYOd-BRxP8--8BbLZ3GF2oEUwiFnNSybdc2r7L1T27LV4pw7BMHGDGTmlmHwFj1-0TZMwmaynWHPoNPrXOk2KKERxlzBcytSKlwPypR88N3u7B56yfDHitC8p3zN3F6YH4FN-I-Qz32ymoMnO1B7baxmcqq1RUxZHZEK27JavCod77mcI40morQgZvz20yoST1f-F~zsXQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
cPLA2 activity in neutrophil lysates of patients with sepsis or with sepsis+bacteremia.
DTT-resistant cPLA2 activity is measured by [14C]AA release from PC vesicles using neutrophil lysates from patients with sepsis or sepsis+bacteremia (“During”) and after recovery (“After”).
